The American Heart Association has published a scientific statement providing prescribers with a list of drugs that can cause or worsen heart failure. Heart failure patients are usually taking medications for multiple medical conditions with resulting risk for drug-drug or drug-condition interactions.
Mandy Davies, Christine Thomson and their practice team from Elgin provide a 'how to' guide on setting up an innovative strategy for managing chronic heart failure, based on their programme that recently won an Innovation in Primary Care Award.
A number of drug classes are used in the treatment of patients with heart failure. This illustrated Back to Basics poster describes the various drugs and their mechanisms of action to give health care professionals and their patients a greater understanding of heart failure management and where sacubitril/valsartan fits into the picture.
This useful Back to Basics poster describes the damaging changes that take place in three key body systems when HF with reduced ejection fraction is left untreated. The sympathetic nervous system, the renin-angiotensin-aldosterone system and the natriuretic peptide system all undergo significant pathophysiological changes as HF progresses.
A really useful reference for your practice, this handy Back to Basics tells you all you need to know about heart failure treatments.
Since the first description of a beta-blocking agent in 1962, this class of drug has become among the most widely used in the management of cardiovascular disease (CVD). Betablockers are now used routinely after a myocardial infarction, in patients with angina pectoris and as an additional therapy in the management of high blood pressure. However, they have traditionally been avoided in heart failure because it was thought that they were potentially harmful. But some large, well-designed randomised controlled trials have provided an overwhelming body of evidence to dispel this myth once and for all.
The BSH’s 18th annual meeting included a number of exciting presentations from some of the leading experts in heart failure. The report includes an update on some of the key trials that reported during the year.
Heart failure affects around three in every hundred people aged 65 to 74 years, and increases with age. About 40% of patients with heart failure will die within one year of diagnosis, underlining the need for prompt diagnosis and effective therapy. In this article we explore what goes wrong in heart failure, and how cardiac resynchronisation can help.
About 40% of patients with heart failure die within one year of diagnosis,underlining the need for more effective management.Nearly one-third of patients with heart failure may have an abnormality in the electrical conducting system of the heart.In this article,we review cardiac resynchronisation and its role in managing chronic heart failure.
HF has a major impact on patients, their families, the NHS and social care services. It still has a poor prognosis, worse than many of the common cancers that also affect older people. It causes significant morbidity and imposes a major cost burden on the health service. This editorial provides an introduction to a special supplement on a first-in-class oral treatment for heart failure.